Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance

Expert Opinion on Biological Therapy

Volumn 15, Issue 12, 2015, Pages 1757-1771

  Schirrmacher, Volker ^a  

^a Immunological and Oncological Center (IOZk)   (Germany)

Author keywords

Anti tumor immunity; Bispecific antibodies; Dendritic cells; Memory T cells; Oncolysis

Indexed keywords

APOPTIN; BISPECIFIC ANTIBODY; CYTOSTATIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; INTERFERON; INTERLEUKIN 4; INTERLEUKIN 5; LUCIFERASE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCLONAL ANTIBODY CD28; MONOCLONAL ANTIBODY CD3; NONSTRUCTURAL PROTEIN 1; ONCOLYTIC NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIRUS; RAC1 PROTEIN; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VIRUS ONCOLYSATE; ANTINEOPLASTIC AGENT; BIOLOGICAL FACTOR; CANCER VACCINE;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; AVULAVIRUS; BONE METASTASIS; BREAST CANCER; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CELL DEATH; COLORECTAL CANCER; COLORECTAL CARCINOMA; CYTOKINE RELEASE; DISEASE FREE SURVIVAL; DNA REPLICATION; DRUG TOLERABILITY; FIBROSARCOMA; GENETIC ENGINEERING; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HOST CELL; HUMAN; IMMUNOGENIC CELL DEATH; IMMUNOSTIMULATION; INNATE IMMUNITY; INOCULATION; KIDNEY CARCINOMA; LIVER METASTASIS; LIVER TUMOR; MELANOMA; MESENCHYMAL STEM CELL; NEUROBLASTOMA; NEWCASTLE DISEASE VIRUS; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; SURVIVAL TIME; T LYMPHOCYTE; TAXONOMY; TH1 CELL; THERAPY EFFECT; THERMOTHERAPY; TRANSGENE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNITY; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS MORPHOLOGY; VIRUS REPLICATION; VIRUS STRAIN; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; GENE THERAPY; GENETICS; IMMUNOLOGY; PROCEDURES; PROSPECTIVE STUDY; TRENDS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL FACTORS; CANCER VACCINES; DRUG RESISTANCE, NEOPLASM; GENETIC THERAPY; HUMANS; NEWCASTLE DISEASE VIRUS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROSPECTIVE STUDIES; VIRUS REPLICATION;

EID: 84945218711     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2015.1088000     Document Type: Review

References (122)

1. Kroemer G, Galuzzi I, Kepp O, Zitvogel I. Immunogenic cell death in cancer therapy. Ann Rev Immunol 2013;31:51-72. This review explains in molecular terms ICD and discusses its relevance to cancer therapy.
2. Guo ZS, Liu Z, Bartlett DL. Oncolytic immunotherapy: dying the right way is a key to eliciting potent antitumor immunity. Front Oncol 2014;4:6-16
3. Schirrmacher V, Fournier P. Editorial: Harnessing oncolytic virus-mediated antitumor immunity. Front Oncol 2014. 4:337-8. Available from: http://journal.frontiersin.org/researchtopic/1613.. In 12 articles, experts from Canada, Germany and the USA emphasize the potential importance of oncolytic viruses on systemic T-cell-mediated anti-tumor immunity.
4. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4:101-17
5. Russel SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012;30:658-70
6. Csatary LK, Gosztonyi G, Szeberenyi J, et al. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 2004;67:83-93
7. Ahlert T, Sauerbrei W, Bastert G, et al. Tumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast and ovarian cancer. J Clin Oncol 1997;15:1354-66
8. Freeman AI, Zakay-Rones Z, Gomori JM, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006;13:221-8
9. Cassel WA, Murray DR. Newcastle disease virus as an antineoplastic agent. Cancer 1965;7:863-8
10. Fournier P, Schirrmacher V. Oncolytic Newcastle disease virus as cutting edge between tumor and host. Biology (Basel) 2013;2:936-75
11. Lam HY, Yeap SK, Rasoli M, et al. Safety and clinical usage of Newcastle disease virus in cancer therapy. J Biomed Biotechnol 2011;2011:718710
12. De Leeuw O, Peeters B. Complete nucleotide sequence of Newcastle disease virus: Evidence for the existence of a new genus within the subfamily Paramyxovirinae. J Gen Virol 1999;80:131-6
13. Fournier P, Wilden H, Schirrmacher V. Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. Int J Oncol 2012;40:287-98
14. Wilden H, Fournier P, Zawatzky R, Schirrmacher V. Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Int J Oncol 2009;34:971-82
15. Hornung V, Ellegast J, Kim S, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006;314:994-7
16. Melchjorsen J, Jensen SB, Malmgaard L, et al. Activation of innate defense against a paramyxovirus is mediated by RIG-I and TLR7 and TLR8 in a cell-type-specific manner. J Virol 2005;79:12944-51
17. Park MS, Garcia-Sastre A, Cros JF, et al. Newcastle disease virus V protein is a determinant of host range restriction. J Virol 2003;77:9522-32. This paper is important to understand the difference between a permissive and a non-permissive host for infection by NDV.
18. Alexander DJ. Newcastle Disease. Kluwer Academic; 1988
19. Miller LT, Yates VJ. Reactions of human sera to avian adenoviruses and Newcastle disease virus. Avian Dis 1971;15(4):303-7
20. Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol 2012;7(3):347-67. This review is recommended for further reading about NDV, cancer therapy and genetically engineered NDV to increase its effectivity.
21. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002;20:2251-66. This clinical trial witnesses the tolerability of NDV even at high doses in cancer patients.
22. Nagai Y, Hamaguchi M, Toyoda T. Molecular biology of Newcastle disease virus. Prog Vet Microbiol Immunol 1989;5:16-64
23. Elankumaran S, Rockemann D, Samal SK. Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death. J Virol 2006;80:7522-34
24. Kumar R, Tiwari AK, Chaturvedi U, et al. Velogenic Newcastle disease virus as an oncolytic virotherapeutics: in vitro characterization. Appl Biochem Biotechnol 2012;167:2005-22
25. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007;35:495-516
26. Chng WC, Stanbridge EJ, Yusoff K, Shafee N. The oncolytic activity of Newcastle disease virus in clear cell carcinoma cells in normoxic and hypoxic conditions: The interplay between VHL and interferon-beta signaling. J Interferon Cytokine Res 2013;33:346-54
27. Elankumaran S, Chavan V, Quiao D, et al. Type I interferon-sensitive recombinant Newcastle disease virus for oncolytic virotherapy. J Virol 2010;84(8):3835-44
28. Fiola C, Peeters B, Fournier P, et al. Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defense. Int J Cancer 2006;119(2):328-38
29. Wilden H, Fournier P, Zawatzky R, Schirrmacher V. Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle disease virus. Int J Oncol 2009;34(4):971-82
30. Wilden H, Schirrmacher V, Fournier P. Important role of interferon-regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus. Int J Oncol 2011;39(2):493-504
31. Krishnamurthy S, Takimoto T, Scroggs RA, Portner A. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 2006;80(11):5145-55
32. Fournier P, Wilden H, Schirrmacher V. Importance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus. Int J Oncol 2012;40(1):287-98
33. Mansour M, Palese P, Zamarin D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol 2011;85(12):6015-23. This paper is of clinical relevance, suggesting that cancer cells which are resistant to chemo- or radiotherapy can be attacked with oncolytic NDV.
34. Lazar I, Yacoov B, Shiloach T, et al. The oncolytic activity of Newcastle disease virus NDV-HUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis Livin. J Virol 2010;84(1):639-46
35. Puhlmann J, Puehler F, Mumberg D, et al. Rac 1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus. Oncogene 2010;29(15):2205-16. This paper suggests a link between tumorigenesis, cancer motility and invasion with susceptibility to oncolysis by NDV.
36. Abdullah JM, Mustafa Z, Ideris A. Newcastle Disease Virus interaction in targeted therapy against proliferation and invasion pathways of Glioblastoma multiforme. Biomed Res Int 2014;2014:386470
37. Koks CAE, De Vleeschouwer S, Graf N, Van Gool SW. Immune suppression during oncolytic virotherapy for highgrade glioma; yes or no? J of Cancer 2015;6:203-17
38. Fabian Z, Csatary CM, Szeberenyi J, Csatary LK. p53-independent endoplasmic reticulum stress-mediated cytotoxicity of a Newcastle disease virus strain in tumor cell lines. J Virol 2007;81:2817-30
39. Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Diff 2008;15:3-12
40. Meng C, Zhou Z, Yu S, et al. Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication. Arch Virol 2012;157:1011-18
41. Meng G, Xia M, Wang D, et al. Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells. Oncotarget 2014;5:6365-74
42. Li Y, Wang LX, Yang G, et al. Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res 2008;68:6889-95
43. Fournier P, Arnold A, Wilden H, Schirrmacher V. Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int J Oncol 2012;40:840-50
44. Jarahian M, Watzl C, Fournier P, et al. Activation of natural killer cells by Newcastle disease virus hemagglutinin-neuraminidase. J Virol 2009;83:8108-21
45. Zeng J, Fournier P, Schirrmacher V Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology 2002;297:19-30
46. Molouki A, Hsu YT, Jahanshiri F, et al. The matrix (M) protein of Newcastle disease virus binds to human Bax trough its BH3 domain. Virol J 2011;8(1):385
47. Washburn B, Weigand MA, Grosse-Wilde A, et al. TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol 2003;170:1814-21
48. Umansky V, Beckhove P, Rocha M, et al. Induction of NO synthesis in macrophages by Newcastle disease virus is associated with activation of nuclear factor-kappa B. Int Immunol 1996;8:491-8
49. Jurianz K, Haas C, Hubbe M, et al. Adhesive function of Newcastle-disease virus hemagglutinin in tumor-host interaction. Int J Oncol 1995;7:539-45
50. Termeer CC, Schirrmacher V, Bröcker EB, Becker JC. Newcastle disease virus infection induces B7-1/B7-2-independent T-cell costimulatory activity in human melanoma cells. Cancer Gene Ther 2000;7:316-23. This study suggests that tumor cell infection by NDV can break tolerance of human tumor-specific T-helper cells.
51. Ertel C, Millar NS, Emmerson PT, et al. Viral hemagglutinin augments peptidespecific cytotoxic T cell responses. Eur J Immunol 1993;23:2592-6
52. Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Int J Oncol 2002;21:85-93. This study characterizes changes in human tumor cells upon infection by NDV. Such pre-apoptotic changes increase the tumor cells immunogenicity.
53. Lorence RM, Katubig BB, Reichard KW, et al. Complete regression of human fibrosarcoma xenografts after local Newcastle disease virus therapy. Cancer Res 1994;54:6017-21
54. Wei D, Sun N, Nan G, et al. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Hum Gene Ther 2012;23(7):700-10
55. Koks CA, Garg AD, Ehrhardt M, et al. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death. Int J Cancer 2015;136:E313-25.. This study demonstrates induction of ICD in situ in a relevant tumor model with subsequent establishment of antitumor immunity, memory and longterm survival.
56. Apostolidis L, Schirrmacher V, Fournier P. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int J Oncol 2007;31:1009-19
57. Altomonte J, Marozin S, Schmidt RM, Ebert O. Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther 2010;18(2):275-84
58. Song KY, Wong J, Gonzalez L, et al. Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV (F3aa)-GFP] for peritoneally disseminated gastric cancer. J Mol Med 2010;88(6):589-96
59. Silberhumer GR, Brader P, Wong J, et al. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther 2010;9(10):2761-9
60. Merigan TCDCE. Finkelstein MS, Clever L, et al. Clinical studies employing interferon inducers in man and animals. Ann N Y Acad Sci 1970;173:746-59
61. Csatary LK, Eckhardt S, Bukosza I, et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detec Prev 1993;17:619-27. An interesting clinical study in which NDV is applied to cancer patients by inhalation to achieve effects, in particular against lung metastases.
62. Freeman AI, Zakay-Rones Z, Gomori JM, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006;13(1):221-8
63. Hotte SJ, Lorence RM, Hirte HW, et al. An optimized clinical regime for the oncolytic virus PV701. Clin Cancer Res 2007;13(3):977-85
64. Cassel WA, Murray DR, Torbin AH. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunological responses. Cancer 1977;40(2):672-9
65. Cassel WA, Murray DR. A ten-year follow-up on stage II malignant melanoma patients treated post-surgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 1992;9(4):169-71
66. Batliwalla FM, Bateman BA, Serrano D, et al. A 15-year follow-up of AJCC stage III malignant melanoma patients treated postsurgically with Newcastle disease virus (NDV) oncolysate and determination of alterations in the CD8+ T cell repertoire. Mol Med 1998;4(12):783-94
67. Plager C, Bowen JM, Fenoglio C, et al. Adjuvant immunotherapy with Newcastle disease virus oncolysate of M. D. Anderson (MDAH) stage III-B malignant melanoma. Proc Am Soc Clin Oncol 1986;5:137a
68. Voit C, Kron M, Schwurzer-Voit M, Sterry W. Intradermal injection of Newcastle disease virus-modified autologous melanoma cell lysate and interleukin-2 for adjuvant treatment of melanoma patients with resectable stage III disease. J Dtsch Dermatol Ges 2003;1(2):120-5
69. Kirchner HH, Anton P, Atzpodien J. Adjuvant treatment of locally advanced renal cancer with autologous virusmodified tumor vaccines. World J Urol 1995;13(3):171-3
70. Khazaie K, Prifti S, Beckhove P, et al. Persistence of dormant tumor cells in the bone marrow of tumor-cell vaccinated mice correlates with long-term immunological protection. Proc Natl Acad Sci USA 1994;91(16):7430-4. This study demonstrates the importance of tumor cell viability for immunogenicity. In addition, it directs the attention to the ear pinna as an optimal site for immunization and to the bone marrow as a site for tumor dormancy and immune control by memory T cells.
71. Schirrmacher V, Schild HJ, Gückel B, von Hoegen P. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens. Immunol Cell Biol 1993;71:311-26
72. Schild H, von Hoegen P, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. II. Augmented tumor-specific T cell response as a result of CD4+ and CD8+ immune T cell cooperation. Cancer Immunol Immunother 1989;28:22-8
73. von Hoegen P, Zawatzky R, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor specific cytolytic T cell activity via induction of interferon-alpha/beta. Cell Immunol 1990;126(1):80-90. This study demonstrates the important role of type I IFNs for adaptive antitumor immune responses.
74. Heicappell R, Schirrmacher V, von Hoegen P, et al. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. I. Parameters for optimal therapeutic effects. Int J Cancer 1986;37:569-77. This early study investigated the efficiency of the vaccine ATV-NDV as a postoperative secondary prevention method.
75. Schirrmacher V, Haas C, Bonifer R, et al. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 1999;6:63-73
76. Schirrmacher V, Ahlert T, Pröbstle T, et al. Immunization with virus-modified tumor cells. Semin Oncol 1998;25:677-96
77. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Ann Rev Immunol 2004;22:745-63
78. Schirrmacher V, Fournier P, Schlag P. Autologous tumor cell vaccines for postoperative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function. Expert Rev Vaccines 2014;13:117-30
79. Ockert D, Schirrmacher V, Beck N, et al. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 1996;2(1):21-8
80. Schlag P, Manasterski M, Gerneth T, et al. Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother 1992;35(5):325-30
81. Schulze A, Kemmner W, Weitz J, et al. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother 2009;58(1):61-9. This paper reports from the only prospective-randomized controlled clinical study involving NDV. Longterm clinical benefit is seen for stage IV colon but not rectum carcinoma patients.
82. Möbus V, Horn S, Stöck M, Schirrmacher V. Tumor cell vaccination for gynecological tumors. Hybridoma 1993;12(5):543-7
83. Pomer S, Thiele R, Staehler G, et al. Tumor vaccination with and without adjuvant interleukin 2 in renal cell carcinoma. A clinical contribution to the development of effective specific immunization. Urologe 1995;34(3):215-20
84. Karcher J, Dyckhoff G, Beckhove P, et al. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virusmodified tumor cells. Cancer Res 2004;64:8057-61
85. Steiner HH, Bonsanto MM, Beckhove P, et al. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol 2004;22:4272-81. This study is exceptional with regard to sophistication in preparation and characterization of the vaccine and with regard to the immunological response monitoring.
86. Liang W, Wang H, Sun TM, et al. Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterology 2003;9(3):495-8
87. Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Exp Rev Vaccines 2009;8(1):1-16
88. Hoover HC Jr, Brandhorst JS, Peters LC, et al. Adjuvant active-specific immunotherapy for human colorectal cancer: 6, 5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993;11(3):390-9
89. Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and III colon cancer: a randomized trial. Lancet 1999;353(9150):345-50
90. Nava S, Lisini D, Pogliani S, et al. Safe and reproducible preparation of functional dendritic cells for immunotherapy in glioblastoma patients. Stem Cells Transl Med 2015. [Epub ahead of print]
91. Zaslavsky E, Hershberg U, Seto J, et al. Antiviral response dictated by choreographed cascade of transcription factors. J Immunol 2010;184:2908-17 This study from systems biology is recommended because it explains reprogramming of DC function following infection by NDV.
92. Fournier P, Arnold A, Schirrmacher V. Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus. J BUON 2009;14(Suppl 1):S111-22
93. Bai L, Koopmann J, Fiola C, et al. Dendritic cells pulsed with viral oncolysates potently stimulate autologous T cells from cancer patients. Int J Oncol 2002;21:685-94
94. Wenner CA, Guler ML, Macatonia SE, et al. Roles of IFN -A and IFN-B in IL-12-induced T helper-1 development. J Immunol 1996;156:1442-7
95. Schirrmacher V, Stücker W, Lulei M, et al. Long-term survival of a breast cancer patient upon immune and virotherapy: a case report. Immunother 2015; Epub ahead of print
96. Mitchell DA, Batich KA, Gunn MD, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature 2015;519:366-9 This study describes an interesting conditioning effect of Th cells upon recruitment to a DC vaccination site.
97. Donnelly O, Ilett E, Kottke T, et al. Cytokine-enhanced intravenous oncolytic virotherapy. Lancet 2014;383:S42
98. Altomonte J, Marozin S, Schmidt RM, Ebert O. Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther 2010;18:275-84
99. Zamarin D, Martinez-Sobrido L, Kelly K, et al. Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther 2009;17:697-706
100. Wu Y, Zhang X, Wang X, et al. Apoptin enhances the oncolytic properties of Newcastle disease virus. Intervirology 2012;55:276-86
101. Janke M, Peeters B, Zhao H, et al. Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int J Oncol 2008;33:823-32
102. Janke M, Peeters B, deLeeuw O, et al. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther 2007;14:1639-49
103. Niu Z, Bai F, Sun T, et al. Recombinant Newcastle disease virus expressing IL-15 demonstrates promising antitumor efficiency in melanoma model. Technol Cancer Res Treat 2014; Epub ahead of print
104. Susta L, Cornax I, Diel DG, et al. Expression of interferon gamma by a highly virulent strain of Newcastle disease virus decreases its pathogenicity in chickens. Microb Pathog 2013;6:73-83
105. Pühler F, Willuda J, Puhlmann J, et al. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes. Gene Ther 2008;15:371-83. This study is remarkable because it shows that NDV can be engineered to produce therapeutic antibodies at the infection site.
106. Shobana R, Samal SK, Elankumaran S. Prostate-specific antigen-retargeted recombinant Newcastle disease virus for prostate cancer virotherapy. J Virol 2013;87:3792-800
107. Pfirschke C, Schirrmacher V. Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus. Int J Oncol 2009;34:951-62. This study suggests that oncolytic NDV can hitchhike on immune T cells to better reach tumor tissue.
108. Mader EK, Maeyama Y, Lin Y, et al. Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res 2009;15(23):7246-55
109. Castleton A, Dey A, Beaton B, et al. Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity. Blood 2014;123:1327-35
110. Aigner M, Janke M, Lulei M, et al. An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. Int J Oncol 2008;32:777-89. This study shows a new way of generating human activated T cells with selective anti-tumor activity without the need of recognizing a tumor-associated antigen. It could be used in case of TAA immune escape variants.
111. Fournier P, Aigner M, Schirrmacher V. Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine. Int J Oncol 2010;37:1203-17
112. Fournier P, Aigner M, Schirrmacher V. Transcriptome analysis and cytokine profiling of näive T cells stimulated by a tumor vaccine via CD3 and CD25. Int J Oncol 2010;37:1439-52
113. Fournier P, Schirrmacher V. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs 2013;27:35-53
114. Schirrmacher V, Schlude C, Weitz J, Beckhove P. Strong T-cell costimulation can reactivate tumor-antigen-specific T cells in late-stage metastasized colorectal carcinoma patients: results from a phase I clinical study. Int J Oncol 2015;46:71-7. This clinical study tests the recombinant bispecific fusion protein anti-HN-anti-CD28 upon attachment to the vaccine ATV-NDV. The results suggest that anergized memory T cells from late-stage cancer patients can be reactivated upon strong T-cell costimulation.
115. Curti BD, Kovacsovics-Bankowski M, Morris N, et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res 2013;73:7189-98
116. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64
117. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23
118. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369:134-44
119. Zamarin D, Holmgaard RB, Subudhi SK, et al. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med 2014;6:226-32. This is a further example how NDV can overcome immunoresistance of tumor cells.
120. Schirrmacher V, Bihari AS, Stücker W, Sprenger T. Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report. Oncol Letters 2014;8:2403-6
121. Schirrmacher V, Jurianz K, Roth C, et al. Tumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLT-CML cultures. Int J Oncol 1999;14(2):205-15
122. Zamarin D, Postow MA. Immune checkpoint modulation: rational design of combination strategies. Pharmacol Ther 2015;150:23-32